The “Companion Diagnostics Development Services Market, 2020-2030:RootsAnalysis:
Key Inclusions
§ A detailed assessmentof the current market landscape of companies offering companion diagnosticsservices, including information on the type of services offered, type ofanalytical technique used and regulatory certifications / accreditations, andother company-specific details (such as year of establishment, company size andgeographical location).
§ Tabulated profiles ofcompanion diagnostics service providers (shortlisted on the basis of the numberof services offered), featuring an overview of the company, its financialinformation (if available), and companion diagnostics-related service portfoliodetails. In addition, each profile includes a list of the likely strategiesthat may be adopted by these players to support future growth.
§ An analysis of thepartnerships and collaborations pertaining to companion diagnostics servicesfrom 2017 to 2019, featuring a detailed set of analyses based on variousparameters, such as the type of partnership, year of partnership, analyticaltechnique used and the most active players.
§ A list ofstakeholders generated based on a detailed analysis of a set of relevantparameters (namely number of clinical trials sponsored by a developer and thetime to market for proprietary personalized medicine products), which areanticipated to partner with companion diagnostics services providers in theforeseen future.
§ A detailedcompetitiveness analysis of companion diagnostics services providers, takinginto consideration the supplier power (based on the year of establishment ofdeveloper) and key specifications, such as portfolio strength, type ofavailable technology platform, number of deals signed between 2017-2019.
§ A comparativeanalysis of the needs of different stakeholders (drug developers, diagnosticdevelopers, testing laboratories, physicians, payers and patients) involved inthis domain.
§ A discussion onvarious steps of the development operations, namely research and development,clinical assessment of the product, manufacturing and assembly, payernegotiation and marketing / sales activities, of a companion diagnostic and thecost requirements across each of the aforementioned stages.
§ An analysis ofcompleted, ongoing and planned clinical trials featuring disease-specificbiomarkers. The analysis highlights the key trends associated with theseclinical studies across various parameters, such as trial start year, trialstatus, phase of development, key indications, type of therapy, biomarkersevaluated, enrolled patient population and regional distribution of trials.
§ A detailed marketforecast, featuring analysis of the current and projected future opportunityacross key market segments (listed below)
- Type of Services
§ Feasibility Studies
§ Assay Development
§ Analytical Validation
§ Clinical Validation
§ Manufacturing
- Type of Analytical Technique
§ in situ hybridization/ Immunohistochemistry
§ Next GenerationSequencing
§ Polymerase ChainReaction
§ Others
- Key Geographical Region
§ North America
§ Europe
§ Asia-Pacific and theRest of World
Transcripts of interviews held with the followingsenior level representatives of stakeholder companies
§ Anton Iliuk (President, Chief Technology Officer TymoraAnalytical Operations)
§ Paul Kortschak (Senior Vice President, Novodiax)
§ Pablo Ortiz (Chief Executive Officer, OWL Metabolomics)
§ Lawrence M. Weiss (Chief Scientific Officer, NeoGenomicsLaboratories)
To request samplepages, please visit this - https://www.rootsanalysis.com/reports/297/request-sample.html
Key QuestionsAnswered
§ Who are the keyplayers that provide services for the development of companion diagnostics?
§ What kind ofpartnership models are commonly adopted by stakeholders in this domain?
§ Whatare the various initiatives undertaken by big pharma players in thisdomain?
§ Whatare cost requirements across each of the development stages of a companiondiagnostics test?
§ Whichdeveloper companies are likely to partner with service provider entities in theforeseen future?
§ Whatare the current and long-term needs of different stakeholders involved in thisdomain?
§ How is the currentand future market opportunity likely to be distributed across key marketsegments?
You may also be interested in the followingtitles:
1. NeoantigenTargeted Therapies Market, 2019-2030
2. BispecificAntibody Therapeutics Market (4th Edition),2019-2030
3. GlobalStem Cells Market: Focus on ClinicalTherapies, 2020-2030
Contact Us
Gaurav Chaudhary
+1 (415) 800 3415
